Use of intravenous magnesium sulfate for the treatment of severe acute asthma in children in emergency department

Uso do sulfato de magnésio venoso para tratamento da asma aguda grave da criança no pronto-socorro

INTRODUCTION

Asthma is a chronic inflammatory disease involving the lower airways that is characterized by variable airflow obstruction and respiratory symptoms. This disease is clinically manifested by recurrent symptoms that often include wheezing, shortness of breath, chest tightness and coughing. In children under five years of age, the symptoms are often variable and nonspecific, making diagnosis difficult.\(^1\)

Asthma is the most common disease in childhood and is a major cause of morbidity, as assessed by school absenteeism, emergency department visits and hospital admissions. In the United Kingdom, asthma affects 5.2 million people, 1.1 million of them children. In the UK, asthma is responsible for approximately 60,000 hospital...
admissions yearly. Although most children in asthma crisis respond well to initial treatment with inhaled bronchodilators and oral corticosteroids, asthma may still cause death in a number of cases. In the United Kingdom, approximately 25 children die from asthma yearly, and poor quality emergency care may be responsible for up to one-third of these deaths.

Severe acute asthma is a medical emergency that must be quickly diagnosed and treated. Airflow obstructions during exacerbations can be severe, resulting in life-threatening respiratory failure. Initial, emergent therapy requires the administration of oxygen, β2 agonists and systemic steroids. For patients who fail to respond to this standard therapy, magnesium sulfate may be a therapeutic option.

Magnesium is an essential cofactor in several enzymatic reactions and helps maintain cell homeostasis. The role of magnesium in asthma is not yet fully understood, but some studies have helped to clarify its mode of action. Magnesium causes bronchodilation via modulation of calcium ion flow, which inhibits the release of acetylcholine from nerve terminals. Magnesium stabilizes T cells, preventing their activation, and inhibits mastocyte degranulation, therefore limiting the production of inflammatory mediators. It also acts to stimulate nitric oxide and prostacyclin production, possibly reducing the severity of asthma.

Most acute asthma patients can be stabilized in an emergency department or an equivalent care setting. According to the Global Initiative for Asthma (GINA) recommendations, during severe exacerbations all patients initially should be given oxygen, β2 agonists, anticholinergics and corticosteroids. The onset of bronchodilatation may occur within minutes, while corticoids may take hours to take effect. Magnesium sulfate may be a therapeutic option for patients who do not respond to these initial therapies.

Although magnesium sulfate is potentially beneficial in severe acute asthma in children who respond poorly to initial therapy with β2 agonists and systemic corticosteroids, its use remains limited in pediatric emergency settings.

In 2007, Barbosa et al. published a review article in The Brazilian Journal of Intensive Care on the use of magnesium sulfate for treating acute asthma patients in the emergency department. They searched Medline for articles published from 2000 to 2006 and included both adult and pediatric patient populations. Considering the relevance of this subject, we performed our search with a specific focus on initial care in the emergency department, broadened our search to include the Lilacs and Cochrane databases and considered articles published from 2000 to 2010. We restricted our search to studies in children that were published in Portuguese, English or Spanish.

This review aimed to assess the effectiveness of intravenous magnesium sulfate in treating severe acute asthma in the pediatric emergency setting, with particular consideration for the indications, dosages, adverse effects and contraindications of magnesium use in asthma crisis.

**METHODS**

The literature on the use of intravenous magnesium sulfate for acute asthma in children in the emergency department was searched via Medline, Lilacs and the Cochrane Database of Systematic Reviews. Articles published in these databases from 2000 to 2010, in Portuguese, English or Spanish, were reviewed. The following keywords were used: asthma, children, emergency and magnesium sulfate. Controlled trials, meta-analyses, guidelines, cohort studies, systematic reviews and classical articles published during the specified timeframe and relevant secondary references were included.

This search yielded 25 articles. Eight controlled trials, three meta-analyses, one retrospective study, eight review articles and one cross-sectional study were included. One case report and three narrative reviews with redundant information were excluded.

**CURRENT LITERATURE EVIDENCE**

Table 1 shows the treatment recommendations from the culled Medline articles on intravenous magnesium sulfate administration in children with acute asthma. Dosages and therapy-related adverse events are shown in table 2.

Ciarallo et al. conducted a randomized, double-blind, placebo-controlled trial involving 31 children (ages between six and 18 years) with moderate and severe acute asthma. Magnesium sulfate was used as intravenous 25 mg/kg (maximum 2 g) doses, within 20 minutes. The pulmonary function was improved and no adverse effect was reported.

Devi et al. conducted a randomized, double-blind, placebo-controlled trial involving 47 children (between one and 12 years) with severe acute asthma. Magnesium sulfate was used as intravenous 100 mg/kg doses, within 35 minutes. The authors report improved signs and symptoms and expiratory peak flow (EPF) above 70%. Only minor adverse effects were reported, such as heartburn, pain, tingling and numbing at the infusion site. No other significant adverse effects, such as hypotension or respiratory depression, were reported.

Gurkan et al. conducted a randomized, double-blind, placebo-controlled trial involving 20 children (ages between six and 16 years) with moderate to severe acute asthma. Magnesium sulfate was administered intravenously in 40 mg/kg (maximum 2 g) doses over 20 minutes. Symptoms and pulmonary function improved significantly in response to
treatment, with no adverse effects reported.\(^{(10)}\)

Ciarallo et al. conducted a randomized, double-blind, placebo-controlled trial involving 30 children (ages between six and 18 years) with moderate to severe acute asthma. Again, magnesium sulfate was administered intravenously in 40 mg/kg (maximum 2 g) doses over 20 minutes. EPF was improved above 80% of expected with marked improvement of pulmonary function, overall. No adverse effects were reported; patellar and brachial reflexes and systolic blood pressures remained normal during the entire study time.\(^{(11)}\)

Scarfone et al. conducted a randomized, double-blind, placebo-controlled trial involving 54 children (ages between one and 18 years). Magnesium sulfate was administered intravenously in 75 mg/kg (maximum 2.5 g) doses over 20 minutes. Analyzing the hospital admissions rate, the authors concluded that the routine use of intravenous magnesium sulfate in children with moderate or severe asthma was not effective. Some minor adverse effects were reported and included vomiting and flushing.\(^{(12)}\)

In a retrospective study, Glover et al. identified 40 patients aged between two months and 15 years who were admitted to an intensive care unit (ICU) in asthma crisis in Florida. Fifteen of the 40 patients with severe acute asthma and who had not received magnesium sulfate required intubation. After magnesium administration, no patient required respiratory support. No adverse cardiovascular effects were reported.\(^{(13)}\)

In a meta-analysis published in 2000, Rowe et al. evaluated the use of magnesium sulfate in conjunction with bronchodilators and systemic corticosteroids in seven studies (five in adult and two in pediatric patient populations) involving a total of 668 patients. The authors found no evidence to support the routine use of magnesium sulfate in all cases of acute asthma. However, magnesium sulfate appeared to be safe and beneficial in the most severe cases.\(^{(14)}\)

The effectiveness of intravenous magnesium sulfate in pediatric asthma crisis was assessed further in two subsequent meta-analyses,\(^{(2,6)}\) with similar results. Five studies, with a total of 182 patients aged between one and 18 years, were assessed. In four of these studies, 25 to 100 mg/kg of magnesium sulfate was administered in conjunction with the standard β2 agonists and systemic corticosteroids. Magnesium sulfate was effective in treating moderate to severe acute asthma in children.

---

### Table 1 - Main results on the use of intravenous magnesium sulfate in acute asthma pediatric patients

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Type of study</th>
<th>Age</th>
<th>Use recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciarallo et al.(^{(11)}) (1996)</td>
<td>1996</td>
<td>Randomized trial</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Devi et al.(^{(9)}) (1997)</td>
<td>1997</td>
<td>Randomized trial</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Gurkan et al.(^{(10)}) (1999)</td>
<td>1999</td>
<td>Randomized trial</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Ciarallo et al.(^{(8)}) (2000)</td>
<td>2000</td>
<td>Randomized trial</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Scarfone et al.(^{(12)}) (2000)</td>
<td>2000</td>
<td>Randomized trial</td>
<td>Pediatric</td>
<td>No</td>
</tr>
<tr>
<td>Rowe et al.(^{(14)}) (2000)</td>
<td>2000</td>
<td>Meta-analysis</td>
<td>Adult and pediatric</td>
<td>No</td>
</tr>
<tr>
<td>Glover et al.(^{(13)}) (2002)</td>
<td>2002</td>
<td>Retrospective</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Cheuk et al.(^{(6)}) (2005)</td>
<td>2005</td>
<td>Meta-analysis</td>
<td>Pediatric</td>
<td>Yes</td>
</tr>
<tr>
<td>Mohammed et al.(^{(2)}) (2007)</td>
<td>2007</td>
<td>Meta-analysis</td>
<td>Adult and pediatric</td>
<td>Yes</td>
</tr>
</tbody>
</table>

---

### Table 2 - Dosage schedule and adverse effects reported

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study group</th>
<th>IV dosage (mg/kg/dose)</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciarallo et al.(^{(11)}) (1996)</td>
<td>31 ED children with moderate-severe acute asthma</td>
<td>25 mg/kg within 20 minutes (Max. 2 g)</td>
<td>None</td>
</tr>
<tr>
<td>Devi et al.(^{(9)}) (1997)</td>
<td>47 ED children with moderate-severe acute asthma</td>
<td>100 mg/kg within 35 minutes</td>
<td>Heart burn, pain and numbing at the infusion site</td>
</tr>
<tr>
<td>Gurkan et al.(^{(10)}) (1999)</td>
<td>20 ED children with moderate-severe acute asthma</td>
<td>40 mg/kg within 20 minutes (Max. 2 g)</td>
<td>None</td>
</tr>
<tr>
<td>Ciarallo et al.(^{(8)}) (2000)</td>
<td>30 ED children with moderate-severe acute asthma</td>
<td>40 mg/kg within 20 minutes (Max. 2 g)</td>
<td>None</td>
</tr>
<tr>
<td>Scarfone et al.(^{(12)}) (2000)</td>
<td>54 ED children with moderate-severe acute asthma</td>
<td>75 mg/kg within 20 minutes (Max. 2.5 g)</td>
<td>Vomiting and flushing</td>
</tr>
</tbody>
</table>

IV - intravenous; ED - emergency department.
resulting in significantly improved respiratory function and a 30% decrease in average hospital admissions.

An online cross-sectional study was conducted in collaboration with two large pediatric emergency medicine associations, one Canadian and one American, to assess for widespread usage of intravenous magnesium sulfate in severe cases of pediatric asthma crisis. In Canada, 124 out of 180 (69%) emergency medicine physicians responded, and 75 out of 108 (69%) eligible emergency departments in the United States responded. Although 88% of respondents overall were aware of magnesium's effectiveness, only 14 of the 199 (7%) departments reported using it to prevent hospital admissions; however 142 of 199 (71%) reported administering magnesium in asthma crisis to prevent ICU admissions. A total of 38% departments reported using magnesium in less than 5% of stable acute episodes of pediatric asthma, while 79% reported its use in 50% or more of patients who show signs of imminent respiratory failure or are otherwise likely candidates for ICU admission. Among 79% of the respondents, fewer than 5% of patients who received intravenous magnesium were discharged to home from the emergency department. No fewer than 24% of respondents reported adverse events of severe hypotension requiring treatment, and 2% observed apnea in patients receiving intravenous magnesium.\(^{(15)}\)

Interestingly, magnesium deficiency has been implicated as a risk factor in asthma exacerbations. One study found that intracellular magnesium levels, as measured in erythrocytes, were significantly lower in children with acute asthma when compared with levels found in the control group.\(^{(16)}\)

Magnesium sulfate was shown to be beneficial in the treatment of moderate to severe asthma in children, and its bronchodilatory and anti-inflammatory effects may recommend its use as an adjuvant therapy in children in asthma crisis who fail to respond to conventional therapy.\(^{(4)}\)

Intravenous administration of magnesium sulfate is safe overall. The most commonly reported side effects are rare and minor, such as flushing, pain and numbness at the infusion site, dry mouth and malaise.\(^{(12)}\) Significant adverse effects were not reported at therapeutic doses. Hypotension was documented for fast (less than 20 minutes) infusions. Magnesium toxicity can result in abnormal atrioventricular (AV) conduction leading to total AV blockade, loss of deep tendon reflexes, muscle weakness, respiratory depression and cardiopulmonary arrest. However, serum magnesium levels generally have to exceed 12 mg/dL to have these effects, and these serum levels are only achieved with doses above 150 mg/kg, well above the therapeutic dose.\(^{(17)}\)

In healthy children, serum magnesium levels range between 1.60 and 2.55 mg/dL. The bronchodilatory effects of magnesium only manifest once serum levels reach 4 mg/dL. After parenteral administration, magnesium is mostly excreted in the urine, and only 1% to 2% is recovered from the stools. Its action is observed within minutes after infusion and lasts for approximately two hours.\(^{(17)}\)

In clinical trials assessing the efficacy of magnesium administration in pediatric asthma crisis, administered magnesium doses ranged between 25 and 100 mg/kg (maximum 2 g). According to the British Guideline on the Management of Asthma (2011), magnesium should be given as no less than 40 mg/kg, not exceeding 2 g/dose.\(^{(18)}\) Pabon et al. recommend dosing at 50 mg/kg, titrating to a serum magnesium level of 4 mg/dL.\(^{(19)}\) This dose was also mentioned by Santana et al.\(^{(20)}\) for the management of severe asthma in children and in a study published in the Indian Journal of Pediatrics in 2010.\(^{(21)}\) Magnesium should be diluted in saline solution and infused over 30 minutes. The dose may be repeated once or twice after four- to six-hour intervals. Alternately, it can be given as a continuous infusion at 10 to 20 mg/kg/hour. Early signs of toxicity are seen with serum levels above 8 mg/dL. Therefore, serum magnesium should be monitored, aiming to keep serum concentrations between 4 and 6 mg/dL.\(^{(17,21)}\)

The concurrent use of magnesium and drugs that reduce its urinary excretion, such as glucagon and potassium-sparing diuretics, may increase serum magnesium levels. Patients taking these medications should be monitored for drug-drug interactions, and medications should be held temporarily when possible.\(^{(5)}\) Magnesium is contraindicated in patients with renal failure (creatinine clearance less than 30 mL/minute), myasthenia gravis, AV block, as well as in patients with myocardial conditions.\(^{(17)}\)

**CLOSING REMARKS**

Intravenous magnesium sulfate was shown to be effective in children with moderate to severe acute asthma who fail to respond to the standard initial therapy. The recommended dose is 50 mg/kg/dose (maximum 2 g/dose).

Literature-reported adverse effects were rare. Contraindications for magnesium administration are renal failure, myasthenia gravis, AV block and myocardial conditions.

Additional studies are required to further assess the safety of magnesium co-administration with drugs that are frequently used in pediatrics.

**RESUMO**

A asma aguda grave é uma emergência médica que deve ser diagnosticada e tratada rapidamente. O tratamento inicial inclui...
broncodilatadores e corticosteróides sistêmicos. Em casos graves, com fraca resposta ao tratamento padrão, o sulfato de magnésio venoso surge como opção terapêutica. O objetivo deste artigo foi revisar a literatura sobre o uso do sulfato de magnésio venoso na asma aguda em crianças no pronto-socorro no que se refere à eficácia, indicação, dosagem, efeitos adversos e contraindicações. Realizada revisão narrativa por meio das Bases de dados Medline, Lilacs e Cochrane Database of Systematic Reviews, entre 2000 e 2010. Utilizados os descritores: asma, crianças, emergência, magnésio sulfato. Incluídos oito ensaios clínicos controlados, três meta-análises, um estudo retrospectivo, oito artigos de revisão e um estudo transversal. A eficácia do magnésio venoso em crianças foi observada por vários autores, com raros efeitos adversos. Seu uso foi indicado para os pacientes com asma aguda moderada e grave que não responderam ao tratamento inicial com broncodilatadores e corticosteróide. As contraindicações em pediatria são poucas. Entre elas está insuficiência renal e bloqueio atrioventricular. Existem poucos relatos da interação do magnésio com drogas de uso pediátrico. Apesar da segurança, na prática, o magnésio venoso é pouco usado na asma aguda em pediatria. Na maioria das vezes, é indicado tardiamente para impedir falência respiratória e internação na unidade de cuidados intensivos. Os estudos demonstram que o magnésio venoso é uma droga eficaz e segura na criança com asma aguda grave, porém o seu uso no pronto-socorro ainda é limitado.

Descritores: Asma/quinioterapia; Criança; Emergência; Sulfato de magnésio/uso terapêutico

REFERENCES


